









市场行情
/
股票
/
nasdaq-nuvl
/

Nuvalent Inc

NUVL

103.800USD

+2.390+2.36%

收盘 12/19, 16:00（美东）报价延迟15分钟

7.50B总市值

亏损市盈率 TTM



Nuvalent Inc

103.800

+2.390+2.36%

概览公司财务分析

概览

公司

财务

分析

关于 Nuvalent Inc 公司

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.

Nuvalent Inc简介



公司代码NUVL

公司名称Nuvalent Inc

上市日期Jul 29, 2021

CEOPorter (James R)

员工数量142

证券类型Ordinary Share

年结日Jul 29

公司地址One Broadway, 14Th Floor

城市CAMBRIDGE

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02142

电话18573577000

网址https://www.nuvalent.com/

公司代码NUVL

上市日期Jul 29, 2021

CEOPorter (James R)

Nuvalent Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Henry E. Pelish, Ph.D.

Chief Scientific Officer

65.96K

Ms. Alexandra (Alex) Balcom, CPA

Chief Financial Officer, Treasurer

13.70K

-34.08%

Ms. Darlene Noci

Chief Development Officer

7.08K

Dr. Joseph Pearlberg, M.D., Ph.D.

Non-Executive Independent Director

5.15K

+105.92%

Ms. Christy J. Oliger

Independent Director

3.97K

Dr. Michael L. Meyers, M.D., Ph.D.

Non-Executive Independent Director

2.65K

Dr. Sapna Srivastava, Ph.D.

Non-Executive Independent Director

2.65K

Dr. Christopher D. Turner, M.D.

Chief Medical Officer

Dr. James R. (Jim) Porter, Ph.D.

President, Chief Executive Officer, Director

Ms. Anna Protopapas

Non-Executive Independent Chairman of the Board

名称

名称/职务

职务

持股

持股变动

Dr. Henry E. Pelish, Ph.D.

Chief Scientific Officer

65.96K

Ms. Alexandra (Alex) Balcom, CPA

Chief Financial Officer, Treasurer

13.70K

-34.08%

Ms. Darlene Noci

Chief Development Officer

7.08K

Dr. Joseph Pearlberg, M.D., Ph.D.

Non-Executive Independent Director

5.15K

+105.92%

Ms. Christy J. Oliger

Independent Director

3.97K

Dr. Michael L. Meyers, M.D., Ph.D.

Non-Executive Independent Director

2.65K

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

Deerfield Management Company, L.P.

25.06%

Fidelity Management & Research Company LLC

13.59%

Paradigm BioCapital Advisors LP

7.34%

The Vanguard Group, Inc.

6.40%

BlackRock Institutional Trust Company, N.A.

4.36%

其他

43.25%

持股股东

占比

Deerfield Management Company, L.P.

25.06%

Fidelity Management & Research Company LLC

13.59%

Paradigm BioCapital Advisors LP

7.34%

The Vanguard Group, Inc.

6.40%

BlackRock Institutional Trust Company, N.A.

4.36%

其他

43.25%

股东类型

持股股东

占比

Hedge Fund

41.63%

Investment Advisor

35.82%

Investment Advisor/Hedge Fund

19.46%

Individual Investor

2.58%

Private Equity

2.18%

Venture Capital

1.74%

Research Firm

1.33%

Sovereign Wealth Fund

0.52%

Pension Fund

0.25%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

440

73.50M

109.27%

-4.34M

2025Q2

438

75.09M

113.13%

-1.35M

2025Q1

443

75.23M

113.38%

-1.51M

2024Q4

428

73.56M

111.20%

-2.43M

2024Q3

401

72.99M

113.51%

-264.12K

2024Q2

367

68.27M

114.85%

-2.37M

2024Q1

344

66.52M

113.46%

-4.79M

2023Q4

296

66.77M

116.76%

+1.56M

2023Q3

249

58.89M

114.16%

-3.80M

2023Q2

230

58.54M

113.63%

-2.82M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Deerfield Management Company, L.P.

17.99M

26.99%

Jun 30, 2025

Fidelity Management & Research Company LLC

9.73M

14.6%

+31.95K

+0.33%

Jun 30, 2025

Paradigm BioCapital Advisors LP

5.27M

7.9%

Jun 30, 2025

The Vanguard Group, Inc.

4.52M

6.77%

+83.60K

+1.89%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.04M

4.56%

+310.84K

+11.39%

Jun 30, 2025

Wellington Management Company, LLP

1.58M

2.36%

+133.99K

+9.29%

Jun 30, 2025

Janus Henderson Investors

1.78M

2.67%

+472.38K

+36.05%

Jun 30, 2025

T. Rowe Price Associates, Inc.

1.76M

2.63%

+338.01K

+23.83%

Jun 30, 2025

Shair (Matthew)

1.64M

2.47%

+2.65K

+0.16%

Jun 18, 2025

State Street Investment Management (US)

1.49M

2.24%

+59.62K

+4.17%

Jun 30, 2025

持股ETF



更新时间: 12月2日周二

机构名称

占比

Tema Oncology ETF

4.14%

ALPS Medical Breakthroughs ETF

2.65%

Global X Guru Index ETF

1.57%

State Street SPDR S&P Biotech ETF

1.16%

Virtus LifeSci Biotech Clinical Trials ETF

0.86%

iShares Health Innovation Active ETF

0.82%

Direxion Daily S&P Biotech Bull 3X Shares

0.72%

ProShares Ultra Nasdaq Biotechnology

0.65%

Invesco Nasdaq Biotechnology ETF

0.64%

iShares Biotechnology ETF

0.39%

Tema Oncology ETF

占比4.14%

ALPS Medical Breakthroughs ETF

占比2.65%

Global X Guru Index ETF

占比1.57%

State Street SPDR S&P Biotech ETF

占比1.16%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.86%

iShares Health Innovation Active ETF

占比0.82%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.72%

ProShares Ultra Nasdaq Biotechnology

占比0.65%

Invesco Nasdaq Biotechnology ETF

占比0.64%

iShares Biotechnology ETF

占比0.39%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Nuvalent Inc的前五大股东是谁？



Nuvalent Inc 的前五大股东如下：
Deerfield Management Company, L.P.持有股份：17.99M，占总股份比例：26.99%。
Fidelity Management & Research Company LLC持有股份：9.73M，占总股份比例：14.60%。
Paradigm BioCapital Advisors LP持有股份：5.27M，占总股份比例：7.90%。
The Vanguard Group, Inc.持有股份：4.52M，占总股份比例：6.77%。
BlackRock Institutional Trust Company, N.A.持有股份：3.04M，占总股份比例：4.56%。